Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner
Open Access
- 29 October 2018
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 1-12
Abstract
Background: Antiangiogenic agents are commonly used in lung and colon cancer treatments, however, rapid development of drug resistance limits their efficacy. Methods: Lentinan (LNT) is a biologically active compound extracted from Lentinus edodes. The effects of LNT on tumor angiogenesis were evaluated by immunohistochemistry in murine LAP0297 lung and CT26 colorectal tumor models. The impacts of LNT on immune cells and gene expression in tumor tissues were determined by flow cytometry, qPCR, and ELISA. Nude mice and IFNγ blockade were used to investigate the mechanism of LNT affecting on tumor angiogenesis. The data sets were compared using two-tailed student’s t tests or ANOVA. Results: We found that LNT inhibited tumor angiogenesis and the growth of lung and colon cancers. LNT treatments elevated the expression of angiostatic factors such as IFNγ and also increased tumor infiltration of IFNγ-expressing T cells and myeloid cells. Interestingly, IFNγ blockade, but not T cell deficiency, reversed the effects of LNT treatments on tumor blood vessels. Moreover, long-lasting LNT administration persistently suppressed tumor angiogenesis and inhibited tumor growth. Conclusions: LNT inhibits tumor angiogenesis by increasing IFNγ production and in a T cell-independent manner. Our findings suggest that LNT could be developed as a new antiangiogenic agent for long-term treatment of lung and colon cancers.Keywords
Funding Information
- National Natural Science Foundation of China (81673004, 81372245)
This publication has 40 references indexed in Scilit:
- Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapyNature Medicine, 2013
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyProceedings of the National Academy of Sciences, 2012
- Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor GrowthCancer Research, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitorsNature Reviews Drug Discovery, 2009
- IP-10 Blocks Vascular Endothelial Growth Factor-Induced Endothelial Cell Motility and Tube Formation via Inhibition of CalpainCirculation Research, 2006
- Selective induction of apoptosis in murine skin carcinoma cells (CH72) by an ethanol extract of Lentinula edodesCancer Letters, 2005
- Antitumor Effects Induced by the Combination of TNP-470 as an Angiogenesis Inhibitor and Lentinan as a Biological Response Modifier in a Rabbit Spontaneous Liver Metastasis ModelSurgery Today, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971